A serum biomarker panel including kallikreins to predict ovarian cancer prognosis and response to chemotherapy

Abstract

Evaluation of: Oikonomopoulou K, Li L, Zheng Y et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer 99(7), 1103–1113 (2008).The use of biomarkers may contribute to a better prediction of the clinical outcome and response to chemotherapy for patients with ovarian cancer. Previous results from the group in the reviewed study have shown an association between the protein expression in solid tumors of different kallikreins, B7-H4 and CA125 and ovarian cancer classification, prognosis and response to chemotherapy. Oikonomopoulou and colleagues have now investigated the role of these proteins in serum samples from 98 patients with ovarian cancer. The odds ratio and hazard ratio were calculated and time-dependent receiver-operating characteristic curves were utilized to evaluate the prognostic performance of the biomarkers. Internal validation of the data was performed based on resampling the original data. The results showed t...